In conclusion, we confirm that HBV reactivation may rarely occur during ibrutinib treatment in OBI/CLL patients, mainly if not only in patients previously treated with CIT
Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study
Quaglia, Francesca Maria;
2022-01-01
Abstract
In conclusion, we confirm that HBV reactivation may rarely occur during ibrutinib treatment in OBI/CLL patients, mainly if not only in patients previously treated with CIT
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
